These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34839992)

  • 1. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Dinc HO; Saltoglu N; Can G; Balkan II; Budak B; Ozbey D; Caglar B; Karaali R; Mete B; Tuyji Tok Y; Ersoy Y; Ahmet Kuskucu M; Midilli K; Ergin S; Kocazeybek BS
    Vaccine; 2022 Jan; 40(1):52-58. PubMed ID: 34839992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required.
    Balkan İİ; Dinc HO; Can G; Karaali R; Ozbey D; Caglar B; Beytur AN; Keskin E; Budak B; Aydogan O; Mete B; Ergin S; Kocazeybek B; Saltoglu N
    Ir J Med Sci; 2023 Feb; 192(1):19-25. PubMed ID: 35344137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers.
    Bayram A; Demirbakan H; Günel Karadeniz P; Erdoğan M; Koçer I
    J Med Virol; 2021 Sep; 93(9):5560-5567. PubMed ID: 34019704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers.
    Demirbakan H; Koçer I; Erdoğan M; Bayram A
    Public Health; 2022 Apr; 205():1-5. PubMed ID: 35219127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Sughayer MA; Souan L; Abu Alhowr MM; Al Rimawi D; Siag M; Albadr S; Owdeh M; Al Atrash T
    Vaccine; 2022 May; 40(20):2841-2847. PubMed ID: 35397946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring SARS CoV-2 antibodies positivity in healthcare workers after inactivated CoronaVac
    Demir M; Çalışkan A; Kaleli İ; Dönmez B; Er H; Ergin Ç
    Germs; 2022 Dec; 12(4):507-518. PubMed ID: 38021180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.
    Saltoğlu N; Dinç HÖ; Balkan İİ; Can G; Özbey D; Beytur AN; Keskin E; Budak B; Aydoğan O; Mete B; Karaali R; Ergin S; Kocazeybek B
    Diagn Microbiol Infect Dis; 2022 Oct; 104(2):115758. PubMed ID: 35878507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
    Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
    Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.
    Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
    J Med Virol; 2022 Oct; 94(10):4719-4726. PubMed ID: 35655438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.
    Soysal A; Gönüllü E; Karabayır N; Alan S; Atıcı S; Yıldız İ; Engin H; Çivilibal M; Karaböcüoğlu M
    Hum Vaccin Immunother; 2021 Nov; 17(11):3876-3880. PubMed ID: 34324409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of Antibody Response to Covishield Vaccine after 6 Months: A Longitudinal Prospective Study.
    Chavhan SS; Dhikale PT; Adsul BB; Kinge KV; Ingale AR; Gokhale CN; Jadhav N
    J Assoc Physicians India; 2024 Jul; 72(7):22-24. PubMed ID: 38990582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.